Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,210,879 shares of the medical research company's stock after purchasing an additional 1,678,154 shares during the period. Wellington Management Group LLP owned 5.65% of Edwards Lifesciences worth $2,458,601,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in EW. Norges Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $610,895,000. Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $555,939,000. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $213,844,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Citigroup lifted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Finally, Truist Financial reiterated a "hold" rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $79.95.

Remove Ads

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock worth $4,513,064 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 1.0 %

EW traded down $0.71 during trading on Tuesday, hitting $71.77. The company had a trading volume of 3,130,437 shares, compared to its average volume of 4,808,167. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $42.19 billion, a PE ratio of 10.30, a P/E/G ratio of 4.82 and a beta of 1.12. The business has a 50-day moving average of $71.59 and a 200-day moving average of $70.59.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.